Amgen - Medical Professionals

Using Reimbursement Connection®

Understanding Your Questions

The Reimbursement Connection® from Amgen provides a broad range of coverage and reimbursement assistance to help you avoid and resolve billing-related problems. Insurance coverage can vary greatly, as can insurer billing requirements. The Reimbursement Connection® is designed to assist you in navigating through the insurance maze.

How Can the Reimbursement Connection® Help You?

Review coverage requirements for Amgen Products
Provide coding and billing-related assistance
Explain payor reimbursement policies
Provide prior authorization support
Provide information regarding claims appeal procedures
Help identify alternative funding sources
Provide information regarding the SAFETY NET® Foundation for medically needy patients

The Reimbursement Connection® has more than fifteen years of experience providing personalized support regarding reimbursement policies, coding and billing procedures, insurance verifications, prior authorization and claims appeals for Amgen products. Our reimbursement experts can answer questions about Medicare, Medicaid, and private insurers, including managed care. One call helps you resolve issues and obtain reimbursement results.

The information provided in this section is of a general nature and for informational purposes only. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters and appropriate coding for a particular patient and/or procedure is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

footer